Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Efzimfotase alfa by Alexion Pharmaceuticals for Hypophosphatasia: Likelihood of Approval
Efzimfotase alfa is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Hypophosphatasia. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's Efzimfotase alfa?
Efzimfotase alfa is a recombinant enzyme commercialized by AstraZeneca, with a leading Phase III program in Hypophosphatasia. According to Globaldata,...